Ticagrelor, co-administered with acetylsalicylic acid, is indicated for the prevention of atherothrombotic events in adult patients with – acute coronary syndromes or- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event. Limitations of use: 90 mg twice daily during the first year after an ACS event followed by 60 mg twice daily for additional 2 years.
Out-licensing: offered for all international market
* Product availability is subject to patent restrictions in countries where applicable patents are in effect
